Company / CapEx per Share
Viridian Therapeutics, Inc.\DE CapEx per Share History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest CapEx per Share
$0.01
FY2024
5-year range
$0.01 / $0.03
FY2020-FY2024
Trend
-68.6%
vs FY2023
Sector context
#136 of 192
Health Care
What the data says
At $0.01, Viridian Therapeutics, Inc.\DE's capex per share ranks #136 of 192 in the Health Care sector. CapEx per Share has declined for 3 consecutive years, from $0.03 in FY2021 to $0.01 in FY2024.
Based on SEC 10-K filings.
0.01 in FY2024 with a 5-year CAGR of -31.0%.
Declined from $0.02 to $0.01 over the past 2 years.
Health Care sector context is included.
CapEx per Share over time
Growth rates
- 3-Year CAGR
- -39.4%
- 5-Year CAGR
- -31.0%
- 10-Year CAGR
- -
Sector benchmark
#136 of 192 in Health CareTop 71% of 192This company $0.01 Sector average $3.54
▼
-99.8% below sector average
Key checks
Key Insights
- Viridian Therapeutics, Inc.\DE's capex per share has declined for 3 consecutive years.
- In FY2024, capex per share decreased 68.6% year-over-year.
- Ranks #136 out of 192 companies in the Health Care sector.
- Peak capex per share was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 1.11 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | CapEx per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $0.01 | -68.6% |
| FY2023 | $0.02 | -19.2% |
| FY2022 | $0.02 | -12.4% |
| FY2021 | $0.03 | +140.2% |
| FY2020 | $0.01 | -70.6% |
| FY2019 | $0.04 | +167.5% |
| FY2018 | $0.02 | -94.9% |
| FY2017 | $0.30 | -16.3% |
| FY2016 | $0.35 | +984.3% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026